Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
文献类型:期刊论文
作者 | Wang, Rong; Wang, Xiaojia; Chen, Zhan-Hong; Niu, Jin; Huang, Yuan; Pan, Jiani; Ye, Weiwu; Cao, Wenming |
刊名 | JOURNAL OF CLINICAL ONCOLOGY
![]() |
出版日期 | 2021-05-20 |
卷号 | 39 |
ISSN号 | 0732-183X |
DOI | 10.1200/JCO.2021.39.15_suppl.e13069 |
资助项目 | National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China |
WOS研究方向 | Oncology |
语种 | 英语 |
WOS记录号 | WOS:000708120300179 |
出版者 | LIPPINCOTT WILLIAMS & WILKINS |
资助机构 | National Natural Science Foundation of China ; Natural Science Foundation of Zhejiang Province, China |
源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/126644] ![]() |
专题 | 中国科学院合肥物质科学研究院 |
作者单位 | 1.Zhejiang Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 2.Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China 3.Zhejiang Canc Hosp, Hangzhou, Peoples R China 4.Burning Rock Biotech, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Med Oncol, Hangzhou, Peoples R China 6.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China |
推荐引用方式 GB/T 7714 | Wang, Rong,Wang, Xiaojia,Chen, Zhan-Hong,et al. Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39. |
APA | Wang, Rong.,Wang, Xiaojia.,Chen, Zhan-Hong.,Niu, Jin.,Huang, Yuan.,...&Cao, Wenming.(2021).Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study..JOURNAL OF CLINICAL ONCOLOGY,39. |
MLA | Wang, Rong,et al."Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.".JOURNAL OF CLINICAL ONCOLOGY 39(2021). |
入库方式: OAI收割
来源:合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。